Dipeptidyl peptidase‐4 inhibitor treatment and the risk of bullous pemphigoid and skin‐related adverse events: A systematic review and meta‐analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Dipeptidyl peptidase‐4 inhibitor treatment and the risk of bullous pemphigoid and skin‐related adverse events: A systematic review and meta‐analysis of randomized controlled trials

Published:2020-08-28 Issue:3 Volume:37 Page:
ISSN:1520-7552
Container-title:Diabetes/Metabolism Research and Reviews
language:en
Short-container-title:Diabetes Metab Res Rev

Author:

Yang Wenjia¹,Cai Xiaoling¹,Zhang Simin¹,Han Xueyao¹,Ji Linong¹^ORCID

Affiliation:

1. Department of Endocrinology and Metabolism Peking University People's Hospital Beijing China

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/dmrr.3391

Reference71 articles.

1. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

2. Inhibitors of dipeptidyl peptidase IV (DP IV, CD26) induces secretion of transforming growth factor-β1 (TGF-β1) in stimulated mouse splenocytes and thymocytes

3. Targeting Dipeptidyl Peptidase IV (CD26) Suppresses Autoimmune Encephalomyelitis and Up-Regulates TGF-β1 Secretion In Vivo

4. Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation

5. Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. The Skin in Diabetes;Textbook of Diabetes;2024-01-12

3. Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review;Diabetes & Metabolic Syndrome: Clinical Research & Reviews;2023-07

4. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidase‐4 inhibitors: A population‐based cohort study using Japanese Latter‐Stage Elderly Healthcare Database;Journal of Diabetes Investigation;2023-03-10

5. Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway;Frontiers in Immunology;2023-01-05